Tag Archives: Amgen

Biogen v. EMD Serono – “A Nest of Limitations”

Posted on October 12, 2020 by Warren Woessner

By now, other commentators have posted on this Fed. Cir. decision (Appeal no. 2019 -1133, Sept. 28, 2020)—and found it to be a routine reversal of a district court’s relying on “source limitations” to find claims to a recombinant IFN-B … Continue reading →

Posted in Anticipation | Tagged , | Leave a comment

Novartis Wins Landmark Biosimilar Approval

Posted on March 9, 2015 by Warren Woessner

Novartis Navigates The FDA-ACA Maze – Gets Approval For Generic Neuprogen. Amgen will soon find itself in a price war with Sandoz – a Novartis company – as it tries to maintain its share of the market for Neuprogen (filgraslim). … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Patents4Life is Six Years Old this Month. Happy Birthday to Us!

Posted on March 3, 2015 by Warren Woessner

Six years ago, In re Kubin caused a flurry of concern among biotech practitioners, and a short article on this decision was the first post on Patents4Life. That was a pretty big “story” at the time but we all had … Continue reading →

Posted in Miscellaneous | Tagged , , , , , , , , , | 4 Comments

FDA Accepts First Biosimilar Application for Review

Posted on July 28, 2014 by Warren Woessner

In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading →

Posted in FDA | Tagged , , , , , , , , , , , , | Leave a comment